Top Markets
#1 MON MON +2,760.99%
#2 $1 is all you need $1 is all you need +1,328.53%
#3 PYTHIA PYTHIA +52.39%
#4 eCash eCash +39.09%
#5 PinGo PinGo +24.63%
#6 Siren Siren +24.18%
#7 Collector Crypt Collector Crypt +23.46%
#8 SAFEcoin SAFEcoin +19.71%
#9 Janction Janction +19.66%
#10 Velvet Velvet +15.56%
Coin of the day
MON MON
설정
언어
한국어
통화
USD
테마
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
주식 순위 #13334
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
주가
$0.30840035
시가총액
$94.37M
변동 (1일)
0.00%
변동 (1년)
-34.60%
국가
FR
거래 Sensorion SA (ALSEN)

카테고리

Healthcare
Sensorion SA (ALSEN)의 수익
Dec 2025 기준 수익 TTM: $-40.05M
Sensorion SA의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-40.05M입니다. 2023년에 회사는 $-24.06M의 수익을 올렸으며 이는 2022년의 수익 $-29.06M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Sensorion SA의 수익 기록 (2011 ~ 2026)
연말 수익
연도 수익 변화
2026 (TTM) $-40.05M 48.91%
2024 $-26.89M 11.77%
2023 $-24.06M -17.20%
2022 $-29.06M 40.87%
2021 $-20.63M 56.49%
2020 $-13.18M -19.26%
2019 $-16.33M 15.05%
2018 $-14.19M 22.11%
2017 $-11.62M 21.72%
2016 $-9.55M 64.80%
2015 $-5.79M 55.42%
2014 $-3.73M 64.62%
2013 $-2.26M 73.88%
2012 $-1.30M 56.52%
2011 $-832.10K 0.00%
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$24.72B -61,819.42%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.17B -12,998.66%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.16B -12,976.69%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -5,437.79%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.66B -4,233.76%
NL